PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
PTPN11 mutation	Juvenile Myelomonocytic Leukemia	PTPN11 mutation	Juvenile Myelomonocytic Leukemia	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3	LY3009120 Sensitive: C3 – Early Trials LY3009120 Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3	venetoclax Resistant: C3 – Early Trials venetoclax Resistant : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3	cytarabine + daunorubicin + mitoxantrone Sensitive: C3 – Early Trials cytarabine + daunorubicin + mitoxantrone Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3	ivosidenib Resistant: C3 – Early Trials ivosidenib Resistant : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3	venetoclax + ABBV 075 Sensitive: C3 – Early Trials venetoclax + ABBV 075 Sensitive : C3
PTPN11 mutation	Non Small Cell Lung Cancer	PTPN11 mutation	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3	azacitidine Sensitive: C3 – Early Trials azacitidine Sensitive : C3
PTPN11 mutation	Acute Myelogenous Leukemia	PTPN11 mutation	Acute Myelogenous Leukemia	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D	dasatinib Sensitive: D – Preclinical dasatinib Sensitive : D

PTPN11 mutation

Associations